<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03844815</url>
  </required_header>
  <id_info>
    <org_study_id>IRB18-1498</org_study_id>
    <nct_id>NCT03844815</nct_id>
  </id_info>
  <brief_title>Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia</brief_title>
  <official_title>Phase 1 Study of Venetoclax in Combination With Decitabine 10-Day Regimen in Subjects With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn about the safety and tolerability of an&#xD;
      experimental drug, Venetoclax, when it is given along with Decitabine in subjects diagnosed&#xD;
      with acute myeloid leukemia (AML).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Anticipated">June 10, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of dose limiting toxicity (DLT)</measure>
    <time_frame>24 months</time_frame>
    <description>Determine the rate of subjects who experience a dose limiting toxicity and the maximum tolerable dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of toxicity with combination regimen</measure>
    <time_frame>24 months</time_frame>
    <description>Levels of toxicity experienced with the combination regimen will be reported using data summaries of adverse events, dose limiting toxicity and other safety parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Overall Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Survival will be measured in months from the date of subject enrollment to the date of death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1 of Treatment will be Decitabine days 1-10 plus Venetoclax ramp up on days 1-3 followed by Venetoclax target dose on days 4-21&#xD;
Cycle 2 of Treatment will be Decitabine days 1-10 plus Venetcolax target dose days 1-21&#xD;
During maintenance Decitabine on days 1-5 plus Venetoclax days 1-21</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Decitabine will be administered intravenously at a dose of 20mg per day for 10 days during Cycle 1 (28 day cycle)&#xD;
Decitabine will be administered intravenously at a dose of 20mg per day for 10 days of Cycle 2 (28 day cycle).&#xD;
Decitabine will be administered intravenously at a dose of 20mg per day for 5 days of each 28 day maintenance cycle</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Venetoclax administered orally on days 1-21 of cycle 1, cycle 2 and maintenance (28 day cycles). Dose levels will be assigned at time of enrollment anywhere from 100mg-400mg. Dose escalation will follow the 3+3 study design.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Phase 1: Dose Escalation Phase&#xD;
&#xD;
               1. High risk AML, including any of the following:&#xD;
&#xD;
                    1. Relapsed or refractory disease&#xD;
&#xD;
                    2. TP53 mutant AML&#xD;
&#xD;
                    3. Adverse risk cytogenetics including any of the following: 3 or more&#xD;
                       abnormalities; deletions involving chromosomes 5, 7, or 17; abnormalities in&#xD;
                       chromosome 11 involving MLL; t(6;9); inv(3) or t(3;3)&#xD;
&#xD;
               2. ECOG performance status 0-2&#xD;
&#xD;
               3. Age 18 years or older&#xD;
&#xD;
               4. Adequate organ function as defined by all of the following:&#xD;
&#xD;
                    1. Creatinine clearance ≥30 mL/min, determined by the Cockroft-Gault formula,&#xD;
                       or measured by a 24 hour urine collection&#xD;
&#xD;
                    2. AST and ALT ≤3 x ULN and bilirubin ≤1.5 x ULN (unless considered due to&#xD;
                       Gilbert's syndrome or of non-hepatic origin i.e. leukemic involvement).&#xD;
&#xD;
               5. Patients must be at least 2 weeks from major surgery, radiation therapy, or&#xD;
                  participation in other investigational trials, and must have recovered from&#xD;
                  clinically significant toxicities related to these prior treatments.&#xD;
&#xD;
               6. Patients must voluntarily sign and date an informed consent, approved by an&#xD;
                  Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the&#xD;
                  i initiation of any screening or study specific procedures.&#xD;
&#xD;
               7. Female patients of childbearing potential must have negative results for a&#xD;
                  pregnancy test&#xD;
&#xD;
               8. Patients must be willing to use appropriate contraception&#xD;
&#xD;
          -  Phase 2: Dose Expansion Phase During the Phase 2 portion of the study, the subject&#xD;
             population will be limited to patients with previously untreated AML with a mutation&#xD;
             in TP53. All other inclusion criteria described above will apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Key exclusion criteria (apply to both Phase 1 and Phase 2 portions of the study):&#xD;
&#xD;
          1. Concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified&#xD;
             in this protocol&#xD;
&#xD;
          2. Patients suitable for and willing to receive intensive induction chemotherapy&#xD;
&#xD;
          3. Use of investigational agents and/or anticancer therapy within 2 weeks of study entry&#xD;
             (with the exception of hydroxyurea, which is permitted before and during Cycle 1 of&#xD;
             therapy until D10, at the discretion of the investigator)&#xD;
&#xD;
          4. Prior treatment with venetoclax, decitabine, or azacitidine&#xD;
&#xD;
          5. Diagnosis of acute promyelocytic leukemia&#xD;
&#xD;
          6. Pregnant or breastfeeding patients&#xD;
&#xD;
          7. Patient known to be positive for HIV&#xD;
&#xD;
          8. Known CNS involvement with AML&#xD;
&#xD;
          9. Evidence of other clinically significant uncontrolled condition(s) including, but not&#xD;
             limited to:&#xD;
&#xD;
               1. Uncontrolled and/or active systemic infection (viral, bacterial or fungal)&#xD;
&#xD;
               2. Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note:&#xD;
                  subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B&#xD;
                  surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B&#xD;
                  core (HBc) antibody negative) or positive anti-HBc antibody from intravenous&#xD;
                  immunoglobulins (IVIG) may participate.&#xD;
&#xD;
               3. An active second cancer that requires treatment within 6 months of study entry&#xD;
&#xD;
         10. Cardiac history including the following:&#xD;
&#xD;
               1. History of CHF requiring treatment or Ejection Fraction ≤ 50%&#xD;
&#xD;
               2. Subject has a cardiovascular disability status of New York Heart Association&#xD;
&#xD;
             Class &gt; 2, defined as:&#xD;
&#xD;
             i. Cardiac disease in which patients are comfortable at rest but ordinary physical&#xD;
             activity ii. Results in fatigue, palpitations, dyspnea, or anginal pain c. Chronic&#xD;
             stable angina&#xD;
&#xD;
         11. Treatment with any of the following within 7 days prior to the first dose of study&#xD;
             drug:&#xD;
&#xD;
               1. Steroid therapy for anti-neoplastic intent&#xD;
&#xD;
               2. Moderate or strong cytochrome P450 3A (CYP3A) inducers&#xD;
&#xD;
         12. Administration or consumption of any of the following within 3 days prior to the first&#xD;
             dose of study drug:&#xD;
&#xD;
               1. Grapefruit or grapefruit products&#xD;
&#xD;
               2. Seville oranges (including marmalade containing Seville oranges)&#xD;
&#xD;
               3. Star fruit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olatoyosi Odenike, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Fridstein</last_name>
    <phone>773-702-9885</phone>
    <email>mfridstein@medicine.bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Of Chicago Medicine Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olatoyosi Odenike, MD</last_name>
      <phone>773-702-3354</phone>
      <email>todenike@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Olatoyosi Odenike, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

